Survodutide · Pep IQ

Origin & What It Is

A Boehringer–Zealand collaboration, built around glucagon

Survodutide is a synthetic peptide co-developed by Boehringer Ingelheim and Danish biotech Zealand Pharma. The collaboration began in 2017, with Boehringer holding worldwide rights and Zealand entitled to royalties and milestone payments. The development name BI 456906 reflects Boehringer's lead position; the international nonproprietary name "survodutide" became the official designation as the asset advanced through Phase 3.

The structural decision that defines this compound is the choice of glucagon as the second receptor target. Tirzepatide pairs GLP-1 with GIP. CagriSema and amycretin pair GLP-1 with amylin. Survodutide pairs GLP-1 with glucagon — and that single choice carries specific biology. Glucagon stimulates hepatic glucose output (normally undesirable in metabolic disease) but also drives energy expenditure, lipolysis, and hepatic fatty-acid oxidation. The GLP-1 component of the dual molecule provides insulinotropic activity that offsets the unwanted hepatic glucose output, leaving the favourable energy expenditure and lipid-handling effects net-positive. That is the biology underneath both the weight-loss programme and the MASH programme.

Zealand Pharma's long-standing work on glucagon analogs (dasiglucagon for severe hypoglycaemia is their other approved product) provided the underlying chemistry. The molecule is acylated to extend half-life to roughly weekly through albumin binding — the same chemical strategy used by semaglutide, tirzepatide, and amycretin. The Phase 3 SYNCHRONIZE-1 topline (April 28, 2026) is the first pivotal readout for any GLP-1/glucagon dual agonist; two more Phase 3 readouts are scheduled through 2026.

Phase 1

First-in-human

✅ Complete

Phase 2

Obesity + MASH

✅ NEJM published

Phase 3

SYNCHRONIZE-1

✅ 16.6% · Apr 2026

Phase 3

SYNCHRONIZE-2 / LIVERAGE

🔄 Reading out 2026

FDA

Submission

⏳ Est. late 2026 / 2027

Science & Mechanism

GLP-1 + glucagon — why this combination targets the liver

Dual Mechanism — Why Glucagon Adds to GLP-1

GLP-1 receptor (appetite, insulin): The same baseline mechanism used by semaglutide and tirzepatide. Central appetite suppression via hypothalamic GLP-1Rs, glucose-dependent insulin secretion from pancreatic beta cells, delayed gastric emptying. Survodutide's GLP-1 component is engineered to be the dominant arm of the dual activity in glycaemic control.

Glucagon receptor (energy expenditure, hepatic fat oxidation): Glucagon activates hepatic fatty-acid oxidation and increases resting energy expenditure — both effects favourable for weight loss. It also reduces hepatic lipid accumulation, which is the biological rationale for the MASH programme. Glucagon would normally elevate blood glucose (its day job is mobilising glycogen), but the paired GLP-1 insulinotropic effect offsets that, leaving the energy expenditure and lipid-handling effects net-positive.

Body composition signal: The SYNCHRONIZE-1 initial readout reported that most weight loss came from fat mass, with lean mass contributing only a small proportion. If the full data confirms this, the body-composition profile may be favourable relative to GLP-1-monotherapy programmes — a meaningful clinical differentiator for older or sarcopenia-prone patients.

Hepatic targeting: Glucagon receptors are expressed densely in the liver. The mechanism gives survodutide a structurally direct route to hepatic fat reduction — which is why Boehringer ran the MASH programme in parallel with the obesity programme, rather than waiting for obesity approval first. The LIVERAGE readout will be the test of whether that mechanistic rationale translates to histologic improvement at Phase 3 scale.

Key data from the SYNCHRONIZE-1 topline (April 28, 2026): once-weekly subcutaneous survodutide in 725 adults with obesity or overweight without T2D, 76 weeks, randomised double-blind placebo-controlled across 14 countries. 16.6% mean body weight loss on the efficacy estimand vs 3.2% placebo. Co-primary endpoints both met (p<0.0001). 85.1% of participants achieved ≥5% body weight reduction vs 38.8% on placebo. Statistically significant waist-circumference reduction. Safety consistent with GLP-1 class — predominantly mild-to-moderate GI events during dose escalation, no new safety concerns observed. Full data scheduled for ADA 2026 Scientific Sessions in June. Phase 2 in MASH (NEJM published) previously demonstrated dose-dependent reductions in liver fat and histologic improvement.

How survodutide compares (Phase 3 obesity headlines): Semaglutide at 68 weeks (STEP 1): ~14.9% weight loss. Tirzepatide at 72 weeks (SURMOUNT-1): ~20.9%. Retatrutide Phase 2: 24.2% at 48 weeks (Phase 3 ongoing). Amycretin Phase 1b/2a: 22.0% at 36 weeks (Phase 3 ongoing). Survodutide at 76 weeks: 16.6%. The weight-loss number sits between semaglutide and tirzepatide. The real differentiator is the MASH track — no other Phase 3 obesity drug has a parallel hepatic indication in pivotal trials.

Benefits & Evidence to Date

What the data shows

⚖️

Weight loss — 16.6% at 76 weeks (Phase 3)

SYNCHRONIZE-1 (n=725, 76 weeks): 16.6% mean weight loss vs 3.2% placebo. 85.1% reached ≥5% reduction. Most weight loss from fat mass. Topline April 28, 2026; full data at ADA June 2026.

● Strong — Phase 3 readout positive

🫀

MASH / hepatic fat reduction

Phase 2 published in NEJM with dose-dependent reduction in liver fat and histologic improvement. Phase 3 LIVERAGE and LIVERAGE-Cirrhosis reading out through 2026 — the differentiator for this compound and the reason Boehringer ran both indications in parallel.

● Moderate — Phase 2 published · Phase 3 pending

🩸

Glycaemic control (T2D)

SYNCHRONIZE-2 (n=752, obesity + T2D) is the dedicated T2D Phase 3, currently reading out. Phase 2 T2D data showed meaningful HbA1c reductions consistent with GLP-1 class. Phase 3 confirmatory readout expected during 2026.

● Limited — Phase 3 readout pending

❤️

Cardiovascular outcomes

SYNCHRONIZE-CVOT is the dedicated long-term cardiovascular safety trial in adults with cardiovascular disease, chronic kidney disease, or cardiovascular risk factors. No readout yet; designed as a longer-running study than the obesity pivotal.

● Limited — Long-term trial ongoing

Safety to Date

Safety profile — consistent with GLP-1 class · no novel signals so far

SYNCHRONIZE-1 topline: GI events consistent with GLP-1 class, mild-to-moderate, mostly during dose escalation. No new safety concerns observed. Full Phase 3 safety data presents at ADA June 2026. Long-term safety beyond 76 weeks remains to be characterised through SYNCHRONIZE-CVOT and post-marketing data once available. Class-warning watch-items (thyroid C-cell, pancreatitis, gallbladder) apply by default until proven otherwise. The glucagon component creates additional theoretical considerations around hepatic enzyme dynamics that the LIVERAGE programme is specifically designed to characterise.

Moderate

GI adverse events — nausea, vomiting, diarrhoea. Most common AE category in SYNCHRONIZE-1, mild-to-moderate severity, concentrated during dose escalation. Boehringer's protocol allows optional re-escalation if GI tolerance is poor. Consistent with the GLP-1 class profile.

Unknown

Long-term hepatic safety — glucagon-receptor agonism is biologically active in the liver. The LIVERAGE / LIVERAGE-Cirrhosis programme is specifically designed to characterise hepatic effects in MASH patients including those with cirrhosis. Until those readouts and the CVOT data are in, long-term hepatic safety in non-MASH populations remains incompletely characterised.

Unknown

Class-level GLP-1 cautions — thyroid C-cell tumour risk (boxed warning carried by semaglutide and tirzepatide), pancreatitis, gallbladder disease, and diabetic retinopathy progression in T2D. Survodutide has not been shown to differ from class on these signals; all class-level cautions apply by default.

Unknown

Counterfeit risk in research peptide markets — survodutide is not commercially available. Any product labelled as such on grey-market peptide sites is by definition unverified. This is one of the higher counterfeit-risk compounds because the genuine molecule has no legitimate supply route outside trials.